Robert F. Williamson, III is currently President and CEO of BioTheryX. Prior to joining BioTheryX, Mr. Williamson served as Chief Executive Officer of both PharmAkea and ATXCo, oncology and fibrosis drug development companies financed through a partnership with Celgene, through PharmAkea’s acquisition by Galecto and ATXCo acquisition by Blade Therapeutics. Prior to PharmAkea and ATXCo, Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which was acquired by Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. In addition to his executive leadership roles, Mr. Williamson has served as a Board member for privately held and publicly traded companies. Most notably, Mr. Williamson served as a member of the Board of Directors of Pharmasset, Inc., where he helped finance, grow, and advance the company to the public markets through its acquisition by Gilead in 2011 for $11 billion. He also served as a member of the Board of Directors of Progen Pharmaceuticals. Currently, Mr. Williamson serves as Chairman of HAYA Therapeutics SA and as a member of the Board of Directors of the Coulter Center in Miami.
Prior to his management roles in industry, Mr. Williamson was a partner with The Boston Consulting Group and was a research assistant for the Federal Reserve Board. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford GSB.